Triglav Investments D.O.O. Acquires 725 Shares of IDEXX Laboratories, Inc. $IDXX

Triglav Investments D.O.O. boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 107.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 1,400 shares of the company’s stock after buying an additional 725 shares during the quarter. Triglav Investments D.O.O.’s holdings in IDEXX Laboratories were worth $751,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in IDXX. Opal Wealth Advisors LLC bought a new position in shares of IDEXX Laboratories during the second quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. increased its position in IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after purchasing an additional 30 shares during the period. Ameritas Advisory Services LLC bought a new position in IDEXX Laboratories during the 2nd quarter worth approximately $36,000. WPG Advisers LLC bought a new position in IDEXX Laboratories during the 1st quarter worth approximately $37,000. Finally, Bank of Jackson Hole Trust lifted its position in shares of IDEXX Laboratories by 328.6% in the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock worth $39,000 after purchasing an additional 69 shares during the period. Institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director owned 262 shares in the company, valued at approximately $169,600.46. The trade was a 89.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total value of $18,491,734.80. Following the completion of the sale, the chief executive officer directly owned 83,311 shares of the company’s stock, valued at approximately $52,650,885.78. This trade represents a 25.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 54,057 shares of company stock worth $34,293,468 in the last 90 days. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $629.51 on Friday. The business’s fifty day moving average is $637.89 and its 200 day moving average is $568.60. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The stock has a market cap of $50.36 billion, a P/E ratio of 52.42, a P/E/G ratio of 4.06 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IDXX shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. Stifel Nicolaus upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and increased their price target for the stock from $640.00 to $700.00 in a report on Friday. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Finally, BTIG Research lifted their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $662.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.